Insulin-Glucose Infusion System for High Blood Sugar

Recruiting in Palo Alto (17 mi)

Overseen ByTimothy W Valk, MD

Age: 18+

Sex: Any

Travel: May Be Covered

Time Reimbursement: Varies

Trial Phase: Phase 1 & 2

Waitlist Available

Sponsor: Admetsys Corporation

No Placebo Group

Trial Summary

What is the purpose of this trial?The purpose of this study is to study the use of a counterbalancing system of glucose and insulin infusion with frequent blood glucose monitoring and combined adaptive algorithm can produce tight glycemic control without hypoglycemia; study to develop a closed loop for use in intensive care units and surgery

Eligibility Criteria

This trial is for adults aged 21-85 with Type 1 or Type 2 diabetes, currently on insulin therapy, and have high blood sugar levels (>150 mg/dl) at the time of study. Their A1c levels should be between 7-9.9%. People who are pregnant, using corticosteroids, or have kidney/liver diseases, electrolyte imbalances, anemia or poor veins for drips cannot join.

Inclusion Criteria

Your blood sugar level at the time of the study is higher than 150 mg/dl.

I am 21-85 years old with diabetes on insulin and my A1c is between 7-9.9%.

Exclusion Criteria

Pregnancy

Your body has abnormal levels of certain minerals like sodium or potassium.

I have kidney or liver disease.

+3 more

Participant Groups

The study tests a system that balances glucose and insulin delivered directly into the bloodstream while frequently checking blood sugar levels. The goal is to maintain stable blood sugar without causing low blood sugar in patients in intensive care units or during surgery.

1Treatment groups

Experimental Treatment

Group I: insulin and glucose infusionExperimental Treatment1 Intervention

trial of experimental technique in outpatient setting; the group under study will be comprised of type 1 and type 2 diabetic individuals ; they will have automated treatment using algorithm which regulates balancing infusions of glucose and/or insulin intravenously without manual intervention; blood glucose target of 80-180 mg/dl will be guide for the automated system